Payment overview · 2025
General Payments
$274,064.17
400 reported records · 12 companies
Healthcare provider profile · identity verified
Todd Jacob Gates, D.O.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · WEST MELBOURNE, FL · NPI 1992702260
Verified facts
What the public records show
CMS Open Payments records show Todd Jacob Gates, D.O. received $274,064.17 in general payments during 2025 across 400 reported records.
ABBVIE INC. accounted for 54.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Maintena, Aristada, Auvelity, Caplyta, Cobenfy, Fanapt, Ingrezza, Invega Sustenna, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 416 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Aristada by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Auvelity by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported COBENFY as an associated drug or biological on 92858 records involving 21456 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Cobenfy by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Invega Sustenna by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Abilify Maintena by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Trintellix by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $148,755.11 | 54.3% | 192 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $51,319.32 | 18.7% | 54 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $38,592.69 | 14.1% | 49 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28,884.09 | 10.5% | 36 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $5,873.35 | 2.1% | 37 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $157.62 | 0.1% | 8 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $136.99 | 0.1% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $114.62 | 0.0% | 5 | 2025 |
| Luye Pharma (USA) Ltd. | Unresolved — no canonical attribution shown | $81.83 | 0.0% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $78.90 | 0.0% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $44.14 | 0.0% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $25.51 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $187,937.00 | 68 |
| Travel and Lodging | $31,952.26 | 109 |
| Honoraria | $26,175.00 | 7 |
| Consulting Fee | $20,615.00 | 6 |
| Food and Beverage | $7,384.91 | 210 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $145,058.08 | 186 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $41,544.32 | 50 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $38,592.69 | 49 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $28,884.09 | 36 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5,873.35 | 37 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $157.62 | 8 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $137.48 | 7 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $136.99 | 9 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $114.62 | 5 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $114.62 | 5 | 2025 |
Source payment records
|
|||||
| ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release |
Drug | Luye Pharma (USA) Ltd. | $81.83 | 3 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $78.90 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $44.14 | 2 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABILIFY MAINTENA abilify maintena |
2025 | Abilify Maintena | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ARISTADA aristada |
2025 | Aristada | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Auvelity auvelity |
2025 | Auvelity | 2024 | 96 | exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 223 | exact normalized | Medicare Part D |
| COBENFY cobenfy |
2025 | Cobenfy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 121 | exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 88 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 416 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
416 | 66 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
96 | 20 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | COBENFY open payments reported associated product |
CMS Open Payments — General Payments 92858 supporting records · 21456 recipient NPIs · example record 1184377695 |
Cobenfy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
223 | 34 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
223 | 34 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
121 | 17 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
88 | 19 |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Quetiapine Fumarate | Quetiapine Fumarate | 499 | 116 |
| Vraylar | Cariprazine Hcl | 416 | 66 |
| Trazodone Hcl | Trazodone Hcl | 315 | 91 |
| Escitalopram Oxalate | Escitalopram Oxalate | 296 | 67 |
| Gabapentin | Gabapentin | 256 | 70 |
| Fluoxetine Hcl | Fluoxetine Hcl | 227 | 52 |
| Caplyta | Lumateperone Tosylate | 223 | 34 |
| Benztropine Mesylate | Benztropine Mesylate | 205 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 196 | 58 |
| Oxcarbazepine | Oxcarbazepine | 195 | 60 |
| Risperidone | Risperidone | 154 | 33 |
| Buspirone Hcl | Buspirone Hcl | 151 | 44 |
| Olanzapine | Olanzapine | 148 | 32 |
| Aripiprazole | Aripiprazole | 128 | 34 |
| Ingrezza | Valbenazine Tosylate | 121 | 17 |
| Clozapine | Clozapine | 118 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 115 | 41 |
| Lurasidone Hcl | Lurasidone Hcl | 115 | 25 |
| Divalproex Sodium | Divalproex Sodium | 112 | 30 |
| Lamotrigine | Lamotrigine | 111 | 31 |
| Auvelity | Dextromethorphan Hbr/Bupropion | 96 | 20 |
| Haloperidol | Haloperidol | 92 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 92 | 23 |
| Sertraline Hcl | Sertraline Hcl | 90 | 27 |
| Topiramate | Topiramate | 88 | 22 |
| Trintellix | Vortioxetine Hydrobromide | 88 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 82 | 25 |
| Clonidine Hcl | Clonidine Hcl | 82 | 18 |
| Nortriptyline Hcl | Nortriptyline Hcl | 75 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 72 | 18 |
| Prazosin Hcl | Prazosin Hcl | 68 | 17 |
| Divalproex Sodium Er | Divalproex Sodium | 67 | 12 |
| Lithium Carbonate | Lithium Carbonate | 66 | 15 |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 60 | 11 |
| Mirtazapine | Mirtazapine | 59 | 19 |
| Levothyroxine Sodium | Levothyroxine Sodium | 48 | 11 |
| Abilify Maintena | Aripiprazole | 47 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 14 |
| Promethazine Hcl | Promethazine Hcl | 47 | 17 |
| Desipramine Hcl | Desipramine Hcl | 41 | 13 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 41 | suppressed |
| Losartan Potassium | Losartan Potassium | 40 | suppressed |
| Levetiracetam | Levetiracetam | 39 | 14 |
| Amantadine | Amantadine Hcl | 38 | suppressed |
| Omeprazole | Omeprazole | 36 | suppressed |
| Perphenazine | Perphenazine | 34 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 31 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 30 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 26 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 26 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 25 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 24 | suppressed |
| Fanapt | Iloperidone | 23 | suppressed |
| Fetzima | Levomilnacipran Hcl | 23 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 22 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 22 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Lisinopril | Lisinopril | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 13 | suppressed |
| Aristada | Aripiprazole Lauroxil | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Cobenfy | Xanomeline Tart/Trospium Chlor | 13 | suppressed |
| Secuado | Asenapine | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $274,064.17 · 400 records | ABBVIE INC. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, Auvelity, CAPLYTA, COBENFY, ERZOFRI EXTENDED-RELEASE, FANAPT, INGREZZA, INVEGA SUSTENNA, LYBALVI, QULIPTA, TRINTELLIX, UBRELVY, UZEDY, VRAYLAR | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abilify Maintena play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error